- The FDA has approved scPharmaceuticals Inc’s (NASDAQ:SCPH) Furoscix (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for congestion due to fluid overload in heart failure patients.
- Furoscix is not indicated for emergencies or in patients with acute pulmonary edema. Furoscix Infusor will deliver only an 80-mg dose.
- The company says Furoscix is the first and only FDA-approved subcutaneous loop diuretic that delivers IV equivalent diuresis at home via the Furoscix Infusor.
- Related: scPharma’s Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients.
- “We are preparing to optimize commercialization efforts to offer FUROSCIX to patients in the first quarter of next year to drive rapid patient adoption to meet the needs of the $5.9 billion addressable market in the U.S,” said John Tucker, President, and CEO.
- Concurrently, scPharmaceuticals secured a $100 million secured debt facility from Oaktree Capital Management, L.P.
- The company will use the funds and cash on hand to repay indebtedness and execute the launch of Furoscix.
- Price Action: SCPH shares are down 7.23% at $4.62 during the premarket session on the last check Monday.
Global Ship Lease Announces Forward Charter Agreements With Hapag-Lloyd For Six ECO 6,900 TEU Ships For ~$393M
LONDON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Global Ship Lease, Inc. (NYSE:GSL) (the "Company") today announced that it has entered into new multi-year charters with Hapag-Lloyd for six ECO 6,900 TEU ships. The
